Tag: Targeted cancer therapy

Dozens of targeted therapy drugs have been approved in the field of oncology, with many identified as tyrosine kinase inhibitors (TKIs). These TKI medications, including many examples of what drugs have the suffix tinib, represent a targeted approach to treating cancer by inhibiting specific enzymes that drive tumor growth.

The term 'fusion drug' can refer to a variety of specialized treatments, each with a unique mechanism of action. What is fusion drug used for depends entirely on its specific therapeutic application, which can range from stopping viral infections to targeting the proteins that drive certain cancers.

Arsenic trioxide (ATO), also known by its brand name Trisenox, has transformed the prognosis for patients with a specific and aggressive type of blood cancer. A key component in modern cancer protocols, ATO is primarily used to treat Acute Promyelocytic Leukemia (APL) by targeting and destroying the specific leukemia cells.